Core Insights - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, specifically through fatty acid synthase (FASN) inhibitors [1][3] - The company will present two oral presentations and participate in a drug development panel at the 9th Annual MASH Drug Development Summit from September 29 to October 1, 2025, in Boston, MA [1] Presentation Details - The first presentation will be led by Dr. Marie O'Farrell, focusing on the mechanism of action of the FASN inhibitor denifanstat in combination with semaglutide or resmetirom, highlighting results from the Phase 2b FASCINATE-2 study [2] - The second presentation by Dr. Wen-Wei Tsai will discuss the anti-fibrotic effect of denifanstat in MASH patients with advanced fibrosis, utilizing AI-based digital pathology techniques [2] Company Overview - Sagimet's lead drug candidate, denifanstat, is an oral, once-daily selective FASN inhibitor aimed at treating metabolic dysfunction associated steatohepatitis (MASH) [3][4] - Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [3][4] - The company has initiated a Phase 1 clinical trial for a second FASN inhibitor, TVB-3567, intended for acne treatment in the U.S. [4] Industry Context - MASH is a severe liver disease affecting over 115 million people globally, with limited approved treatments available [5] - The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH aims to provide a non-stigmatizing diagnosis [5]